 |
PDBsum entry 3f88
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
E.C.2.7.11.1
- non-specific serine/threonine protein kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
E.C.2.7.11.26
- [tau protein] kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[tau protein] + ATP = O-phospho-L-seryl-[tau protein] + ADP + H+
|
|
2.
|
L-threonyl-[tau protein] + ATP = O-phospho-L-threonyl-[tau protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[tau protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[tau protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[tau protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[tau protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
|
Bioorg Med Chem Lett
17:2017-2029
(2009)
|
|
PubMed id:
|
|
|
|
|
| |
|
Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
|
|
M.Saitoh,
J.Kunitomo,
E.Kimura,
Y.Hayase,
H.Kobayashi,
N.Uchiyama,
T.Kawamoto,
T.Tanaka,
C.D.Mol,
D.R.Dougan,
G.S.Textor,
G.P.Snell,
F.Itoh.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Glycogen synthase kinase-3beta (GSK-3beta) is implicated in abnormal
hyperphosphorylation of tau protein and its inhibitors are expected to be a
promising therapeutic agents for the treatment of Alzheimer's disease. Here we
report design, synthesis and structure-activity relationships of a novel series
of oxadiazole derivatives as GSK-3beta inhibitors. Among these inhibitors,
compound 20x showed highly selective and potent GSK-3beta inhibitory activity in
vitro and its binding mode was determined by obtaining the X-ray co-crystal
structure of 20x and GSK-3beta.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
G.E.Atilla-Gokcumen,
L.Di Costanzo,
and
E.Meggers
(2011).
Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase 3β.
|
| |
J Biol Inorg Chem,
16,
45-50.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.Saeki,
M.Machida,
Y.Kinoshita,
R.Takasawa,
and
S.Tanuma
(2011).
Glycogen synthase kinase-3β2 has lower phosphorylation activity to tau than glycogen synthase kinase-3β1.
|
| |
Biol Pharm Bull,
34,
146-149.
|
 |
|
|
|
|
 |
S.Y.Lu,
Y.J.Jiang,
J.Lv,
J.W.Zou,
and
T.X.Wu
(2011).
Role of bridging water molecules in GSK3β-inhibitor complexes: insights from QM/MM, MD, and molecular docking studies.
|
| |
J Comput Chem,
32,
1907-1918.
|
 |
|
|
|
|
 |
I.Buch,
D.Fishelovitch,
N.London,
B.Raveh,
H.J.Wolfson,
and
R.Nussinov
(2010).
Allosteric regulation of glycogen synthase kinase 3β: a theoretical study.
|
| |
Biochemistry,
49,
10890-10901.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |